Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.

Abstract: Provided is a cell containing a nucleic acid sequence having a parvovirus terminal repeat sequence, wherein the cell overexpresses single strand binding protein compared to a cell of a wild-type (WT) strain of the same species. Also provided is a nucleic acid vector containing a nucleic acid sequence having a parvovirus terminal repeat sequence and a nucleic acid sequence encoding a single strand binding protein. Methods of using said nucleic acid vector to propagate and purify nucleic acid vectors involved in the production of parvovirus vector particle production are also described.

Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.

Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.

Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.

Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.

Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.

Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.

Abstract: The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates. The invention also relates to compositions which comprise more than one insulinotropic and/or incretin and/or gut peptide molecules present as part of a fusion or conjugate and to uses and formulations thereof.

Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.

Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.

Abstract: The invention relates to porcine endogenous retrovirus (PERV) and novel methods of identification, isolation and screening via polynucleotide sequences. It also relates to use of said methods in providing a pig that does not express porcine endogenous retrovirus. The organs, tissues and cells of said pig being capable of use for xenotransplantaion.

Abstract: Unitary transceiving units employ a multiple carrier, time-division-multiple-access (TDMA), time-division-duplex (TDD protocol to conduct concurrent wireless voice and data communications wherein a first transceiving base station unit tethered to a network interface wirelessly communicates to a second, mobile transceiving unit. The mobile transceiving unit wirelessly transmits and receives packetized voice and data information that is separated and routed to respective voice or data networks. The unitary mobile transceiving unit thus functions as a concurrent voice phone and data communications terminal/computer.

Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be at least 2 to 14% smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.

Abstract: The present invention provides a bacterium having a genome that is genetically engineered to be at least 2 to about 20% smaller than the genome of its native parent strain. A bacterium with a smaller genome can produce a commercial product more efficiently. The present invention also provides methods for deleting genes and other DNA sequences from a bacterial genome. The methods provide precise deletions and seldom introduces mutations to the genomic DNA sequences around the deletion sites. Thus, the methods can be used to generate a series of deletions in a bacterium without increasing the possibility of undesired homologous recombination within the genome. In addition, some of the methods provided by the present invention can also be used for replacing a region of a bacterial genome with a desired DNA sequence.

Abstract: The invention relates to porcine endogenous retrovirus (PERV) and novel methods of identification, isolation and screening via polynucleotides sequences. It also relates to use of said methods in providing a pig that does not express porcine endogenous retrovirus. The organs, tissues and cells of said pig being capable of use for xenotransplantation.

Abstract: The present invention discloses that a bacterium having a genome that is genetically engineered to be at least 10% smaller than the genome of its native parent strain has better transformation competence. Specific E. coli strains, having significantly reduced genome sizes, are disclosed which are highly transformation competent. A medium and methodology is taught which enables transformation efficiencies to be increased further.

Abstract: The device for assembling a push V-belt for a continuously variable automatic transmission wherein the push V-belt consists of a plurality of push elements (1) movably interconnected that form an endless belt and of two ring sets (2, 2′) has a centering ring (3) for lodging the first ring set (2) and fixing the individual push elements (1) and a circular ring (4) upon the lodged push V-belt and externally partly surrounding it, the ring having an inner outline adapted to the appertaining outer outline of the push V-belt so that a radial force acts upon each individual push element (1) in direction to the axle that traverses perpendicularly to the radial plane the central point of the circle formed by the push V-belt.

Abstract: The device for assembling a push V-belt for a continuously variable automatic transmission wherein the push V-belt consists of a plurality of push elements (1) movably interconnected that form an endless belt and of two ring sets (2, 2′) has a centering ring (3) for lodging the first ring set (2) and fixing the individual push elements (1) and a circular ring (4) upon the lodged push V-belt and externally partly surrounding it, the ring having an inner outline adapted to the appertaining outer outline of the push V-belt so that a radial force acts upon each individual push element (1) in direction to the axle that traverses perpendicularly to the radial plane the central point of the circle formed by the push V-belt.